Which GLP-1 Program Is Right for You? Compare Options
It is late, the house is quiet, and you have a few program websites open in different tabs. You have already made peace with the idea that a GLP-1 might be the medical option you have been circling for months. If you have put in years of real effort and watched it stop paying off, that is not a discipline problem. Bodies change, and biology can work against effort that has not slipped at all. Now the choices multiply: semaglutide or tirzepatide, brand-name or compounded, insurance or cash-pay. That is a fair place to be stuck.
Here is the part that should take some pressure off: this is an information gap, not a decision you have to make alone or get exactly right on the first try. You do not have to pick your own medication or guess at your own dose. A licensed provider decides whether a prescription is appropriate for you, and which one, based on your health history.
Your job on this page is smaller and calmer: understand how the options differ, see what a provider weighs, and know what to ask before you pick a program. No page can tell you in advance what you will be prescribed, and that is good news. It means the answer is tailored to your body, not to a checkout button.
This content is for general education and is not medical advice. Talk with a licensed provider about your situation.
Program options to review
Most people get a GLP-1 prescription through one of four kinds of programs. Each can work. They differ mainly in who pays, which medications are on the table, and what is included.
Brand-name through insurance
Your own provider or a telehealth program prescribes an FDA-approved medication, and your plan helps pay. Coverage for weight management varies widely, and many plans require prior authorization.
Manufacturer self-pay
You pay cash for a brand-name medication through the manufacturer's own self-pay or savings program, with a prescription from a licensed provider. Terms and eligibility rules vary by program.
Cash-pay telehealth
An online program with licensed prescribers. Some prescribe brand-name medications; some prescribe compounded semaglutide or tirzepatide, which are not FDA-approved. Fees and what they cover vary.
In-person clinic or primary care
A primary care provider, obesity medicine clinic, or specialist. More face-to-face monitoring; the medication is usually billed through insurance or paid separately.
Transformation Health does not accept payment from providers. How we make money.
Price is only one dimension, and the advertised price is rarely the full cost. Prices vary by program and dose. For how cash-pay costs are structured, see cash-pay telehealth costs and the medication pricing guide. If you are weighing a primary care visit against an online program, see PCP vs. telehealth.
How the programs actually differ
Strip away the marketing and a few distinctions matter: which molecule, what it is approved for, how you take it, what the trials showed, side effects, coverage, brand-name versus compounded, and total cost.
Mechanism. Semaglutide is a GLP-1 receptor agonist; it acts on one receptor. Tirzepatide acts on two, the GIP and GLP-1 receptors[6]. These receptors are involved in appetite signaling and in how quickly the stomach empties, which is why people often describe a quieter relationship with food on these medications. If that food noise got louder for you in your late thirties or forties, that lines up with perimenopause, when estrogen decline shifts fat storage toward the midsection and changes how appetite signals work. That is biology, not a lapse in effort. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) describes weight management medications as helping some people feel less hungry or full sooner[1]. A dual-mechanism medication is not automatically right for everyone.
What each is approved for. The brand-name medications approved for weight management are Wegovy (semaglutide, Novo Nordisk) and Zepbound (tirzepatide, Eli Lilly). Both are approved, with a reduced-calorie diet and more physical activity, for adults with obesity or adults with overweight and at least one weight-related condition[5][6]. Wegovy injection is also approved for ages 12 and up with obesity, to lower the risk of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight, and (under accelerated approval) for a type of fatty liver disease, noncirrhotic MASH with moderate to advanced fibrosis[5]. Zepbound is also approved to treat moderate to severe obstructive sleep apnea in adults with obesity[6]. The same molecules are sold under other names for type 2 diabetes: Ozempic (semaglutide)[8] and Mounjaro (tirzepatide)[7].
Form and dosing frequency. Wegovy comes as a once-weekly injection or a once-daily tablet[5]. Zepbound is a once-weekly injection, in a pen or a vial[6]. There is no FDA-approved oral tirzepatide. Both labels start at a low dose and step up gradually, about every 4 weeks for the injections, to limit stomach side effects[5][6]. A weekly injection is less frequent but involves a small needle; a daily tablet means no needle but a daily routine. It depends on what you will actually stick with.
| Wegovy (semaglutide) | Zepbound (tirzepatide) | |
|---|---|---|
| Receptors | GLP-1 | GIP and GLP-1 |
| Forms | Once-weekly injection; once-daily tablet | Once-weekly injection (pen or vial) |
| Starting dose | Injection 0.25mg weekly; tablet 1.5mg daily | 2.5mg weekly |
| Usual maintenance | Injection 1.7mg or 2.4mg weekly (up to 7.2mg for some adults); tablet 25mg daily | 5mg, 10mg, or 15mg weekly |
| Other approved uses | Cardiovascular risk reduction; MASH (injection) | Obstructive sleep apnea with obesity |
| Boxed warning | Risk of thyroid C-cell tumors | Risk of thyroid C-cell tumors |
Sources: Wegovy prescribing information, Revised 06/2026[5]; Zepbound prescribing information, Revised 08/2026[6]. As of October 16, 2026.
What the trials showed. Each of these trials studied the manufacturers’ brand-name medicines, not compounded versions.
- In STEP 1, adults without diabetes took semaglutide 2.4mg weekly or placebo for 68 weeks. Average weight loss was 14.9% with semaglutide versus 2.4% with placebo[2].
- In SURMOUNT-1, adults without diabetes took tirzepatide 5mg, 10mg, or 15mg weekly or placebo for 72 weeks. Average weight loss was 15.0%, 19.5%, and 20.9%, versus 3.1% with placebo[3].
- Those were separate trials, so they cannot be compared directly. SURMOUNT-5 compared the two head to head: 751 adults with obesity but without type 2 diabetes took the highest dose they tolerated of tirzepatide (10mg or 15mg) or semaglutide (1.7mg or 2.4mg) for 72 weeks. Average weight loss was 20.2% with tirzepatide and 13.7% with semaglutide[4]. The trial was open-label and funded by Eli Lilly, which makes tirzepatide, and it did not test the higher 7.2mg semaglutide dose now on the Wegovy label[4][5].
Results vary. Trial results describe study participants and are not a prediction for any individual. Some people do better on semaglutide than some people on tirzepatide. For more detail, see semaglutide vs. tirzepatide, compared.
Side effects and risks. Both medications cause similar stomach and bowel side effects, mostly during dose increases. In SURMOUNT-5, the most common side effects in both groups were gastrointestinal and mostly mild to moderate[4]. The most common side effects on the Wegovy label include nausea, diarrhea, vomiting, constipation, abdominal pain, unusual skin sensations (dysesthesia), headache, fatigue, indigestion, dizziness, bloating, burping, gas, reflux, and hair loss[5]. On the Zepbound label they include nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion, injection site reactions, fatigue, allergic reactions, burping, hair loss, and reflux[6]. Both labels carry a boxed warning about thyroid C-cell tumors seen in rodents; neither medication should be used by people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2, or with a known serious allergy to the medication. Both also warn about pancreatitis, gallbladder disease, low blood sugar with insulin or sulfonylureas, kidney injury from dehydration, and severe gastrointestinal reactions[5][6].
Coverage. Insurance coverage for weight management differs by plan, and many plans that cover these medications require prior authorization. Ozempic and Mounjaro are FDA-approved for type 2 diabetes, not for weight management[7][8], so ask your plan how it handles each brand. If your plan does not cover a brand-name medication, manufacturer self-pay programs are another route. See prior authorization for GLP-1s and manufacturer savings programs.
Brand-name or compounded. Some cash-pay programs prescribe compounded semaglutide or tirzepatide. Compounded medications are not FDA-approved, the FDA does not review them for safety, effectiveness, or quality, and they are not the same as Wegovy or Zepbound[10]. None of the trials above studied compounded products. More on this below.
Total cost. Prices vary by program and dose. Compare the total cost: the medication at your likely maintenance dose, dose increases, provider visits, labs, shipping, membership fees, and cancellation terms. A low starting price can rise as the dose goes up.
What your provider actually weighs
This is where the decision anxiety should ease. You are not the one who has to make the final call. At most programs, a licensed provider reviews your health history and decides whether a medication is appropriate. Here is what usually goes into that review.
BMI and weight-related conditions
The Wegovy and Zepbound labels cover adults with obesity, or with overweight plus at least one weight-related condition. NIDDK describes this as a BMI of 30 or higher, or 27 or higher with a condition such as high blood pressure or type 2 diabetes.
Health history and contraindications
A provider checks for a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and asks about pancreatitis, gallbladder disease, and other factors on the labels.
Current medications
GLP-1 medications slow stomach emptying, which can affect how other oral medicines are absorbed. A provider reviews your current prescriptions and supplements.
Other conditions, prior use, and preference
Heart disease, sleep apnea, or type 2 diabetes can point toward a particular label. Prior GLP-1 use and your preference for a weekly injection or daily tablet matter too.
BMI is where a lot of the “am I even a candidate” worry lives, so here are the actual numbers. According to NIDDK, a health care professional may prescribe a weight management medication for an adult with a BMI of 30 or higher, or 27 or higher with weight-related health problems such as high blood pressure or type 2 diabetes[1]. STEP 1 and SURMOUNT-1 used similar entry criteria[2][3]. BMI alone does not decide anything, though. A licensed provider makes that determination based on your full health picture. For the specifics, see the GLP-1 eligibility requirements.
If you use a telehealth program, ask whether the prescriber is licensed in your state and whether a live video visit is required where you live.
What to check before using compounded GLP-1 medication
Compounded semaglutide and tirzepatide are often the reason cash-pay telehealth prices differ from brand-name prices, so it helps to know what they are. They are prepared by compounding pharmacies, not by the manufacturers of the brand-name medicines. They are not FDA-approved, they have not been through the clinical trials described above, and they may differ from brand-name products in formulation, purity, and potency[10].
Their legal status has also changed. FDA has determined that the tirzepatide injection shortage (decision reissued December 19, 2024) and the semaglutide injection shortage (February 21, 2025) are resolved, and the periods during which FDA did not intend to act against compounders over shortage-dependent conditions have ended (FDA page current as of 04/01/2026)[9]. Availability depends on federal and state law and FDA action, and can change.
If a program offers a compounded product, ask which pharmacy prepares it, whether it is a state-licensed 503A pharmacy or an FDA-registered 503B outsourcing facility, whether each batch is tested, and whether the program states plainly that the medication is not FDA-approved. Our guide to choosing a compounded GLP-1 provider has the full checklist.
Questions to ask any program
Bring these to any program you are considering, whatever the type:
- Prescriber. Who reviews my health history (a physician, nurse practitioner, or physician assistant), and are they licensed in my state?
- Medications. Which medications and forms do you prescribe? Brand-name, compounded, or both?
- If compounded. Which pharmacy prepares it, what is its license type, and is each batch tested?
- Cost. What is the total monthly cost at my starting dose and at the maintenance dose? What is billed separately (visits, labs, shipping, membership)?
- Insurance. Do you work with my insurance or help with prior authorization, or is it cash-pay only?
- Commitment. Is there a minimum commitment or prepayment, and how do I cancel?
- Follow-up. How do I reach a provider about side effects, and how are dose changes handled?
- Stopping or switching. What happens if the medication is not working or I cannot tolerate it?
Transformation Health does not accept payment from providers. How we make money.
How the process should work
At most telehealth programs, you fill out a health history form, a licensed provider reviews it (sometimes with labs or a video visit), and the provider decides whether a prescription is appropriate. If one is written, it goes to a pharmacy: a retail or mail-order pharmacy for brand-name medications, or a compounding pharmacy for compounded products. A proper program includes follow-up with a licensed provider while you take the medication, including dose adjustments and help with side effects.
Whichever path you choose, plan for the medication to be long term. In SURMOUNT-4, adults who had lost an average of 20.9% on tirzepatide and were then switched to placebo regained an average of 14.0% of body weight over the next 52 weeks, while those who continued lost a further 5.5%[11]. Plan any change with your prescriber. For the full walkthrough, see how the process works and the broader guide to getting a GLP-1 prescription online.
We're relaunching soon
We're relaunching as an independent GLP-1 guide. Leave your email and we'll let you know when your free custom report is ready.
Get StartedInformation About Compounded Medications
Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality[10]. Compounded semaglutide and tirzepatide are not the same as brand-name products such as Wegovy, Ozempic, Zepbound, or Mounjaro. They may differ in formulation, purity, and potency.
This content is for general education and is not medical advice. Talk with a licensed provider about your situation. Transformation Health is an independent GLP-1 guide. It does not provide medical care, prescribe, or sell medication. A licensed provider decides whether a prescription is appropriate.
Results vary. Trial results describe study participants and are not a prediction for any individual.
Wegovy and Ozempic are trademarks of Novo Nordisk A/S. Zepbound and Mounjaro are trademarks of Eli Lilly and Company. Transformation Health is not affiliated with or endorsed by these companies.
Citations
[1] National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Prescription Medications to Treat Overweight & Obesity.” https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity (Accessed 2026-10-16. BMI thresholds; how the medications work.)
[2] Wilding JPH, Batterham RL, Calanna S, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” N Engl J Med. 2021;384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/ (STEP 1: 14.9% vs 2.4% at 68 weeks.)
[3] Jastreboff AM, Aronne LJ, Ahmad NN, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” N Engl J Med. 2022;387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/ (SURMOUNT-1: 15.0%, 19.5%, 20.9% vs 3.1% at 72 weeks.)
[4] Aronne LJ, Horn DB, le Roux CW, et al. “Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.” N Engl J Med. 2025;393(1):26-36. https://pubmed.ncbi.nlm.nih.gov/40353578/ (SURMOUNT-5: 751 adults, open-label, 20.2% vs 13.7% at 72 weeks.)
[5] U.S. Food and Drug Administration. WEGOVY (semaglutide) injection and tablets, prescribing information. Revised 06/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf
[6] U.S. Food and Drug Administration. ZEPBOUND (tirzepatide) injection, prescribing information. Revised 08/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806Orig1s041correctedlbl.pdf
[7] U.S. Food and Drug Administration. MOUNJARO (tirzepatide) injection, prescribing information. Revised 04/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866Orig1s052lbl.pdf
[8] U.S. Food and Drug Administration. OZEMPIC (semaglutide) injection, prescribing information. Revised 05/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/209637Orig1s039lbl.pdf
[9] U.S. Food and Drug Administration. “FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize.” Content current as of 04/01/2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize (Accessed 2026-10-16.)
[10] U.S. Food and Drug Administration. “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.” Content current as of 10/01/2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss (Accessed 2026-10-16.)
[11] Aronne LJ, Sattar N, Horn DB, et al. “Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.” JAMA. 2024;331(1):38-48. https://pubmed.ncbi.nlm.nih.gov/38078870/ (Regain after stopping tirzepatide.)